A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer

Completed · Phase 2

Conditions studied: Thyroid Cancer

In brief

This will be a Phase II, open label study to establish the effect of once-daily oral doses of ZD6474 100mg in subjects with locally advanced or metastatic hereditary medullary thyroid cancer in whom no standard therapeutic option is available.

Key facts

Study ID

NCT00358956

Run by

Genzyme, a Sanofi Company

People needed

19

Starts

2006-08-01

Expected to finish

2014-05-01

Last updated by the study team

2017-01-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Provision of written informed consent
• Previously confirmed histological diagnosis of locally advanced or metastatic hereditary medullary thyroid carcinoma without standard therapeutic options
• Aged 18 or over and a life expectancy of more than 12 weeks

You may not qualify if…

• The last dose of prior chemo/radiation received less than 4 weeks before the start of study therapy
• Congenital long QT syndrome or 1st degree relative with unexplained sudden death under 40 years of age, history of arrhythmia

Where it is running

• Research Site — Little Rock, Arkansas, United States
• Research Site — Boston, Massachusetts, United States
• Research Site — St Leonards, Australia
• Research Site — Sherbrooke, Quebec, Canada
• Research Site — Pisa, Italy
• Research Site — Utrecht, Netherlands
• Research Site — Bucharest, Romania
• Research Site — Madrid, Spain
• Research Site — Basel, Switzerland

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.